DATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGODATABASE · 2,000+ PEER-REVIEWED CITATIONS INDEXEDCOMPOUND LIBRARY · 100+ EVIDENCE-GRADED RECORDSGRADE A EVIDENCE · 45 COMPOUNDS WITH MULTIPLE HUMAN RCTSHUMAN EVIDENCE · 97 COMPOUNDS WITH HUMAN STUDY DATAVENDOR DIRECTORY · 11 RESEARCH VENDORS TRACKEDCLINIC DIRECTORY · 10 TELEHEALTH PROVIDERS VETTEDCOA RECORDS · 7 BATCH CERTIFICATES ON FILELIVE DATABASE · UPDATED 2D AGO
Home/Compounds/Mazdutide
GLP-1 agonistRx required

Mazdutide

Also known as: IBI362 · LY3305677

Investigational dual GLP-1 / glucagon receptor agonist licensed to Innovent Biologics.

B
Grade B
Human observational studies
Human studies28
PubMed citations30
Routesubcutaneous
Regulatory (US)Rx required
Last verified2 days ago

Mechanism of action

Oxyntomodulin analog that activates both GLP-1 and glucagon receptors. Weekly dosing.

Evidence summary

28
Human studies
30
PubMed citations
25
Clinical trials
B
Evidence grade

Evidence summary in progress. See the citations section below for the underlying research papers.

Dosing protocols

Educational information only. Consult a licensed provider before using any peptide.
Administration routes
subcutaneous

Side effects & safety

No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.

Interactions

No documented drug interactions on file.

Regulatory status

United States
Not FDA approved

Investigational — Phase 3 trials ongoing (primarily in China)

Compounding
Not permitted

Not available via 503A/503B compounding pharmacies.

Regulatory data last verified 4/19/2026

Clinical trials

NCT07517042Achieving Sustained Weight Control Via Exercise, Nutrition & Drugs (Mazdutide) (ASCEND- 1 Trial)Recruiting · N/A · Obesity · n=420NCT06143956A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or OverweightRecruiting · Phase 2 · Obesity · n=1217NCT06817356A Phase 2, Double-Blind, Proof of Concept Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderActive Not Recruiting · Phase 2 · Alcohol Use Disorder · n=300NCT07469800A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Participants With Mild to Moderate Hypertension Complicated by Overweight/Obesity Who Have Not Received Antihypertensive Drug TreatmentNot Yet Recruiting · Phase 3 · Overweight · n=336NCT07083154Efficacy, Safety, and Tolerability of a GLP-1/GCG Dual Receptor Agonist in Type 2 Diabetes With Early Dementia: A Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled TrialRecruiting · Phase 3 · Dementia, Mild · n=420NCT07417306A Multicenter, Randomized, Open-label, Parallel-controlled, Phase 3 Study to Compare the Efficacy and Safety of HDM1005 Versus Mazdutide in Subjects With T2DM Inadequate Glycemic Control by Metformin Monotherapy or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorNot Yet Recruiting · Phase 3 · Type 2 Diabetes · n=912NCT06184568A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Versus Semaglutide in Chinese Participants With Early Type 2 Diabetes and Obesity (DREAMS-3)Active Not Recruiting · Phase 3 · Type 2 Diabetes · n=349NCT07255209A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）Recruiting · Phase 3 · Adolescents With Obesity or Overweight With Weight-Related Comorbidities · n=180NCT07000955Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg Administered Multiple Times in Chinese Patients With Moderate to Severe ObesityActive Not Recruiting · Phase 1 · Obesity · n=98NCT06937749A Randomized, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy and Safety of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Recruiting · Phase 2 · Metabolic Dysfunction-associated Steatohepatitis (MASH) · n=165NCT04904913A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese SubjectsCompleted · Phase 2 · Overweight/ Obesity · n=328NCT06536023A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of IBI362 in Chinese Obese Adolescent SubjectsCompleted · Phase 1 · Adolescents With Obesity · n=36

Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →

Citations

PMID 41488145Li X, Chen Z et al. · Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies.Frontiers in endocrinology (2026)HumanPMID 41054801Son JW, le Roux CW et al. · Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.Endocrine reviews (2026)HumanPMID 41478576Elmendorf AJ, Yousefian M et al. · IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.Pharmacological research (2026)HumanPMID 41787737Abulehia A, Ayesh H et al. · Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.Endocrinology, diabetes & metabolism (2026)HumanPMID 41407860Guo L, Zhang B et al. · Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature (2026)HumanPMID 41389801Pan XF, Fang ZZ et al. · Obesity in China: current progress and future prospects.The lancet. Diabetes & endocrinology (2026)HumanPMID 41711462Chan ZH, Omar AS et al. · Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis.Cardiology in review (2026)PMID 41820018Abdul Fasi M · Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes.Expert opinion on therapeutic patents (2026)PMID 41948476Lempesis IG, Dalamaga M · Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.Metabolism open (2026)HumanPMID 41407859Zhu D, Zhao J et al. · Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature (2026)HumanPMID 41333115Abdelrahman RM, Musa TH et al. · Harnessing GLP-1 Receptor Agonists for Obesity Treatment: Prospects and Obstacles on the Horizon.Journal of obesity (2025)HumanPMID 41025406Neff GW · Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.Diabetes, obesity & metabolism (2025)HumanPMID 40421736Ji L, Jiang H et al. · Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine (2025)HumanPMID 40479843Dong W, Bai J et al. · Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis.EBioMedicine (2025)HumanPMID 41030857Cheng W, Chen Z et al. · Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.Frontiers in endocrinology (2025)HumanPMID 40832785Bhattachar SN, Tham LS et al. · Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.Diabetes, obesity & metabolism (2025)HumanPMID 41028652Shirley M · Mazdutide: First Approval.Drugs (2025)HumanPMID 39968298Liu S, Hu J et al. · Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.Frontiers in endocrinology (2025)HumanPMID 39952695Kokkorakis M, Chakhtoura M et al. · Emerging pharmacotherapies for obesity: A systematic review.Pharmacological reviews (2025)HumanPMID 40081498Bailey CJ, Flatt PR et al. · Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.Peptides (2025)Human

Showing 20 of 30 papers. View all on PubMed →